End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
911.7 INR | -1.48% |
|
+9.63% | +38.76% |
May. 15 | Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion | RE |
Apr. 25 | Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 21.47 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 4.53 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.76% | 1.34B | D | ||
+54.07% | 809B | C+ | ||
+39.64% | 624B | B | ||
-7.05% | 351B | C+ | ||
+15.44% | 319B | B- | ||
+5.72% | 289B | C+ | ||
+14.49% | 240B | B+ | ||
+0.82% | 219B | A+ | ||
+14.75% | 220B | B- | ||
+7.42% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLS Stock
- Ratings Glenmark Life Sciences Limited